]>
IRCT138903114085N1 IRCT 2008-02-20 Research assistant of Guilan University of Medical Science Effects of atorvastatin on asthmatic patients Effects of atorvastatin on lung function in asthmatic patients under treatment with high dose inhaled steroid or oral steroid 2008-02-20 anticipated 50 Complete https://irct.ir/trial/4275 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 1 Asthma. Intervention 1: Atrovastatin 40mg tablet, daily, for 8 weeks. Intervention 2: Placebo 40mg tablet, daily, for 8 weeks.
public Seyyed Ali Alavi Foumani
Sardar Jangal street, Razi hospital
Rasht Iran (Islamic Republic of) 41448-95655 +98 13 1554 1001 rrc@gums.ac.ir Guilan University of Medical Sciences scientific Fatemeh Nejatifar
Razi hospital, Sardar Jangal street
Rasht Iran (Islamic Republic of) 41448-95655 +98 13 1554 1001 dr_f_nejatifar@yahoo.com Guilan University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: aged 18 to 70 years, moderate to severe persistent asthma, under maintenance therapy with high dose inhaled corticosteroid and any dose of oral corticosteroid, under stable medication for the four preceding weeks before randomization, being admitted to respiratory clinic of Razi medical center (Rasht, Guilan province) Exclusion criteria: current smoking or ex-smoking more than 5 pack–year, pregnancy, lactation, any associated diseases, receiving statins or any statin interacting drugs, occurrence of any asthmatic attack during the study 18 years 70 years Both J45 Asthma Treatment - Drugs Placebo Atrovastatin 40mg tablet, daily, for 8 weeks Placebo 40mg tablet, daily, for 8 weeks FEV1. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry. FVC. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry. FEV1/FVC. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry. FEF25-75%. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry. Hs-CRP. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample,micg/ml. ESR. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample, mm/h. Asthma control level. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: asthma control test (ACT). Creatinine kinase(CPK). Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample, IU/L. Liver function test. Timepoint: at the begining of the study and every 1-month interval until 2months. Method of measurement: blood sample,IU/L. (Beta hCG) pregnancy test. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample, mIU/ml. Research assistant of Guilan University of Medical Science Approved 2007-05-21 Vice-chancellor for Research, Guilan university of medical sciences Vice-chancellor for Research building, Shahid Siadati street, Namjoo avenue, Rasht Iran (Islamic Republic of)